Human liver-spheroid toxicity tests for Indian drug developers and CROs
TL;DR Tissuegrove runs a contract lab that tests drug candidates on small 3D balls of human liver cells, to catch liver toxicity before animal studies and trials. Indian biotechs, generic makers working on new molecules and CROs pay per compound. It starts with standard models, not custom printed organs.
Liver injury is a common reason drug candidates fail late, and animal livers often react differently from human ones. A 2026 study comparing hepatocytes from four species found human and monkey cells far more sensitive to known liver-toxic drugs than rat and dog cells[1]. Indian drug developers still have few local options for human 3D testing. A 2026 review of India's position names academic liver-on-chip and skin-on-chip work at IISc and NCCS, but notes that CDSCO has no formal guidance on using such data[2]. So most firms that want 3D liver data send samples abroad, pay in foreign currency and wait on shipping.
What it does, in regulatory terms: preclinical in-vitro testing services only. Tissuegrove does not test on patients and makes no diagnostic claims. Its reports support, and do not replace, the studies a regulator asks for.
The core offer is a fixed panel. A client sends a compound and Tissuegrove doses human liver spheroids over about two weeks, reads cell death, liver function markers and gene expression, and returns a report that compares the result with reference drugs of known human outcome. Add-ons cover repeat dosing, metabolite questions and side-by-side species comparison.
We reframed the seed, which pitched a bioprinted organ for each patient. Personally I think that's too slow, too costly and too unproven for routine decisions. The 2026 four-species study found static spheroids captured expected toxicity best, with perfused chips adding only modest gains[1]. So Tissuegrove sells the simpler, validated format first. Patient-derived models can come later, when a paying client asks for them.
The users are toxicologists and discovery leads. The payers are Indian biotech startups, mid-size pharma firms with new-molecule programmes, and CDMOs and CROs that want to offer 3D data without building a lab. The 2026 India review names large Indian contract research firms as likely partners for this kind of work[2]. Overseas services such as a Swiss firm's liver injury service set the reference price, though it publishes no list price[3].
The 2023 amendment to India's New Drugs and Clinical Trials Rules opened room for non-animal data, and ICMR set aside 5% of its Small Extramural Grant for such methods in 2025[2]. BIRAC programmes, including BioE3, fund preclinical model work[2]. India's pharma exports reached Rs. 2.74 lakh crore in FY26[4], and more of that pipeline now includes new molecules.
There is no public figure for India's 3D in-vitro toxicology services market. The adjacent figure is broad: India's domestic pharma market was valued at Rs. 5.30 lakh crore in FY26[4]. Treat that as context only. The useful signal is narrower - a funded grant line for non-animal methods and named Indian CDMOs looking for academic and commercial partners[2].
One Swiss company sells liver microtissues and a liver injury testing service[3]. A Bengaluru biotech has a liver organoid platform for drug discovery, alongside its therapy pipeline[5]. Indian academic groups run liver and skin chips, mostly for research. The gap is a commercial Indian lab with a fixed panel, published reference results and rupee pricing.
| Difficulty | Hard (60/100) |
| Starting capital | ₹2–3.5 Cr |
| Time to launch | 12–18 months |
The science is published. The hard part is proving your lab gives the same answer every time, which means good cell supply, tight quality systems and a reference-drug study you publish openly. Sales cycles are slow because toxicologists trust data and couldn't care less about your pitch deck.
No single licence covers the lab, but several rules shape what you can claim and which cells you can use.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI make the safety call on a compound. A qualified toxicologist owns every conclusion in the report.
Want to work out the AI layer for Tissuegrove? Talk to Yash →
Here's what can go south -
This suits a founder with a toxicology or cell-biology PhD and some CRO sales experience. If you're hoping to sell bioprinted organs quickly then this isn't it. Prove one thing before raising - that your panel ranks 20 reference drugs correctly, and that three Indian clients pay for a pilot.
Plan for roughly ₹2–3.5 Cr for the lab, cell supply, quality systems and a published reference-drug study.
There is no single licence, but you need ethics documentation for human cells and should present reports as decision support, since CDSCO has no formal guidance on 3D data yet.
Yes. Drug makers worldwide want human-relevant liver data. Check what your local regulator accepts for non-animal methods and its rules on human cells.
The free Tissuegrove validation kit has the line-by-line capital breakdown, the effort scoring, the rules and ethics checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for toxicologists and CRO heads, and 5 assumptions to test. Download the kit →
Thinking about building Tissuegrove or something close to it? The make-or-break work is a reference-drug study that buyers believe and a steady supply of good cells, and I can help you plan both. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.